2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2444

Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies
Abstract Number: 2445

Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Abstract Number: 2446

Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Abstract Number: 2447

Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Abstract Number: 2448

Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Abstract Number: 2449

Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Abstract Number: 2450

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Abstract Number: 2451

Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Abstract Number: 2452

The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Abstract Number: 2453

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Abstract Number: 2454

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Abstract Number: 2455

Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Abstract Number: 2456

Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Abstract Number: 2457

Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Abstract Number: 2458

Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].